KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Operating Leases (2019 - 2025)

Jazz Pharmaceuticals has reported Operating Leases over the past 7 years, most recently at $50.9 million for Q4 2025.

  • Quarterly results put Operating Leases at $50.9 million for Q4 2025, up 30.7% from a year ago — trailing twelve months through Dec 2025 was $50.9 million (up 30.7% YoY), and the annual figure for FY2025 was $50.9 million, up 30.7%.
  • Operating Leases for Q4 2025 was $50.9 million at Jazz Pharmaceuticals, down from $53.4 million in the prior quarter.
  • Over the last five years, Operating Leases for JAZZ hit a ceiling of $156.6 million in Q2 2021 and a floor of $38.8 million in Q1 2025.
  • Median Operating Leases over the past 5 years was $69.4 million (2024), compared with a mean of $74.1 million.
  • Biggest five-year swings in Operating Leases: crashed 50.28% in 2022 and later skyrocketed 30.7% in 2025.
  • Jazz Pharmaceuticals' Operating Leases stood at $87.2 million in 2021, then dropped by 17.62% to $71.8 million in 2022, then decreased by 17.56% to $59.2 million in 2023, then tumbled by 34.25% to $38.9 million in 2024, then surged by 30.7% to $50.9 million in 2025.
  • The last three reported values for Operating Leases were $50.9 million (Q4 2025), $53.4 million (Q3 2025), and $55.1 million (Q2 2025) per Business Quant data.